4.95
2 Seventy Bio Inc stock is traded at $4.95, with a volume of 1.31M.
It is down -0.40% in the last 24 hours and up +90.38% over the past month.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment focusing on researching, developing and commercializing potentially transformative treatments for cancer.
See More
Previous Close:
$4.97
Open:
$4.96
24h Volume:
1.31M
Relative Volume:
1.28
Market Cap:
$259.07M
Revenue:
$44.12M
Net Income/Loss:
$-156.25M
P/E Ratio:
-1.6124
EPS:
-3.07
Net Cash Flow:
$-154.61M
1W Performance:
+0.00%
1M Performance:
+90.38%
6M Performance:
+2.91%
1Y Performance:
-1.20%
2 Seventy Bio Inc Stock (TSVT) Company Profile
Name
2 Seventy Bio Inc
Sector
Industry
Phone
339-499-9300
Address
60 BINNEY STREET, CAMBRIDGE
Compare TSVT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TSVT
2 Seventy Bio Inc
|
4.95 | 259.07M | 44.12M | -156.25M | -154.61M | -3.07 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-06-24 | Downgrade | Goldman | Neutral → Sell |
Jan-31-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jan-31-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Oct-30-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
Oct-12-23 | Initiated | Citigroup | Buy |
Sep-13-23 | Downgrade | Goldman | Buy → Neutral |
Sep-12-23 | Downgrade | Guggenheim | Buy → Neutral |
Jul-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Oct-31-22 | Initiated | Guggenheim | Buy |
May-02-22 | Initiated | Goldman | Buy |
Feb-10-22 | Initiated | SVB Leerink | Outperform |
Jan-06-22 | Initiated | Cowen | Outperform |
Nov-09-21 | Initiated | Canaccord Genuity | Buy |
Nov-08-21 | Initiated | Morgan Stanley | Overweight |
Nov-08-21 | Initiated | Wedbush | Outperform |
View All
2 Seventy Bio Inc Stock (TSVT) Latest News
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World
In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - Fierce Pharma
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire
Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive
Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World
Barclays PLC Sells 132,019 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Fmr LLC Has $701,000 Stock Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2 Seventy Bio Inc Stock (TSVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2 Seventy Bio Inc Stock (TSVT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Baird William D III | President and CEO |
Mar 17 '25 |
Sale |
4.95 |
5,092 |
25,180 |
1,121,034 |
Eatwell Victoria | Chief Financial Officer |
Mar 17 '25 |
Sale |
4.95 |
2,592 |
12,817 |
444,387 |
Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
11,095,936 |
54,702,964 |
0 |
Kynam Global Healthcare Master | 10% Owner |
Mar 11 '25 |
Sale |
4.93 |
5,142,111 |
25,350,607 |
0 |
Snow Jessica | See Remarks |
Jan 06 '25 |
Sale |
2.79 |
5,114 |
14,289 |
147,365 |
Snow Jessica | See Remarks |
Jan 03 '25 |
Sale |
2.94 |
1,000 |
2,936 |
152,479 |
Snow Jessica | See Remarks |
Jan 07 '25 |
Sale |
2.64 |
186 |
491 |
147,179 |
Leschly Nick | Director |
Jan 03 '25 |
Sale |
2.94 |
85,978 |
252,423 |
1,234,498 |
Leschly Nick | Director |
Jan 06 '25 |
Sale |
2.78 |
892 |
2,478 |
1,233,606 |
Eatwell Victoria | Chief Financial Officer |
Jan 03 '25 |
Sale |
2.94 |
1,013 |
2,974 |
339,076 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):